Rubinstein C, Fletcher D R, Shulkes A, Hardy K J
Department of Surgery, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
Aust N Z J Surg. 1992 Nov;62(11):892-6. doi: 10.1111/j.1445-2197.1992.tb06945.x.
Calcitonin gene-related peptide (CGRP) is a potent vaso-active peptide. Typically, it is elevated in the plasma of patients with medullary thyroid cancer (MTC), but is undetectable in the plasma of healthy individuals. Some symptoms associated with MTC could be caused by elevated CGRP. The plasma level of CGRP was measured in patients with recurrent MTC at rest and again after intravenous pentagastrin to further elevate the CGRP. When normal subjects received pentagastrin the CGRP level still remained below the detectable threshold (< 4 pmol/L). The CGRP levels did not correlate with the patients' blood pressure but a rise in CGRP was associated with a rise in heart rate. As not all patients showed symptoms, further investigation examined the possibility of plasma elevation of somatostatin, a known inhibitor, preventing responses but no change was found. Similarly, examination of the patient plasma for CGRP fractions did not reveal any increased breakdown.
降钙素基因相关肽（CGRP）是一种强效血管活性肽。通常，甲状腺髓样癌（MTC）患者血浆中该肽水平会升高，但健康个体血浆中无法检测到。一些与MTC相关的症状可能由CGRP水平升高引起。对复发性MTC患者静息时的血浆CGRP水平进行了测量，静脉注射五肽胃泌素后再次测量，以进一步提高CGRP水平。正常受试者接受五肽胃泌素后，CGRP水平仍低于可检测阈值（<4 pmol/L）。CGRP水平与患者血压无关，但CGRP升高与心率加快有关。由于并非所有患者都出现症状，进一步研究探讨了已知抑制剂生长抑素血浆水平升高从而阻止反应的可能性，但未发现变化。同样，对患者血浆中的CGRP组分进行检测，未发现任何降解增加的情况。
